IBIO

Company Overview — What Does iBio, Inc. Do?

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas. iBio, Inc. (IBIO) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Thomas F. Isett and employs approximately 100 people, headquartered in NEW YORK, New York. With a market capitalization of $67M, IBIO is one of the notable companies in the Healthcare sector.

iBio, Inc. (IBIO) Stock Rating — Avoid (April 2026)

As of April 2026, iBio, Inc. receives a Avoid rating with a composite score of 28.0/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.IBIO ranks #3,993 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, iBio, Inc. ranks #691 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IBIO Stock Price and 52-Week Range

iBio, Inc. (IBIO) currently trades at $2.20. The stock lost $0.00 (0.2%) in the most recent trading session. The 52-week high for IBIO is $4.99, which means the stock is currently trading -56.0% from its annual peak. The 52-week low is $0.56, putting the stock 294.7% above its annual trough. Recent trading volume was 514K shares, suggesting relatively thin trading activity.

Is IBIO Overvalued or Undervalued? — Valuation Analysis

iBio, Inc. (IBIO) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.29x, versus the sector average of 2.75x. The price-to-sales ratio is 242.96x, compared to 1.66x for the average Healthcare stock.

At current multiples, iBio, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

iBio, Inc. Profitability — ROE, Margins, and Quality Score

iBio, Inc. (IBIO) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -42.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -37.2% versus the sector average of -33.1%.

On a margin basis, iBio, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -4080.3% (sector: -66.1%). Net profit margin stands at -3951.0%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IBIO Debt, Balance Sheet, and Financial Health

iBio, Inc. has a debt-to-equity ratio of 14.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 9.04x, indicating strong short-term liquidity.

IBIO has a beta of 1.69, meaning it is more volatile than the broader market — a $10,000 investment in IBIO would be expected to move 68.6% more than the S&P 500 on any given day. The stability factor score for iBio, Inc. is 13/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

iBio, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, iBio, Inc. reported revenue of $300,000 and earnings per share (EPS) of $-0.09. Net income for the quarter was $-24M. Operating income came in at $-25M.

In Q2 2026, iBio, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.09. Net income for the quarter was $-9M. Operating income came in at $-9M.

In Q1 2026, iBio, Inc. reported revenue of $100,000 and earnings per share (EPS) of $-0.11. Net income for the quarter was $-6M. Operating income came in at $-6M.

In FY 2025, iBio, Inc. reported revenue of $400,000 and earnings per share (EPS) of $-1.75. Net income for the quarter was $-18M. Revenue grew 77.8% year-over-year compared to FY 2024. Operating income came in at $-19M.

Over the past 8 quarters, iBio, Inc. has demonstrated a growth trajectory, with revenue expanding from $225,000 to $300,000. Investors analyzing IBIO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IBIO Dividend Yield and Income Analysis

iBio, Inc. (IBIO) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IBIO Momentum and Technical Analysis Profile

iBio, Inc. (IBIO) has a momentum factor score of 40/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 45/100 reflects moderate short selling activity.

IBIO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, iBio, Inc. (IBIO) ranks #691 out of 838 stocks based on the Blank Capital composite score. This places IBIO in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IBIO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IBIO vs S&P 500 (SPY) comparison to assess how iBio, Inc. stacks up against the broader market across all factor dimensions.

IBIO Next Earnings Date

No upcoming earnings date has been announced for iBio, Inc. (IBIO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IBIO? — Investment Thesis Summary

The quantitative profile for iBio, Inc. suggests caution. The quality score of 22/100 flags below-average profitability. The value score of 22/100 indicates premium valuation. High volatility (stability score 13/100) increases portfolio risk.

In summary, iBio, Inc. (IBIO) earns a Avoid rating with a composite score of 28.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IBIO stock.

Related Resources for IBIO Investors

Explore more research and tools: IBIO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IBIO head-to-head with peers: IBIO vs AZN, IBIO vs SLGL, IBIO vs VMD.